Successful Treatment of Severe Recurrent Aphthous Ulcer with Scutellaria baicalensis Georgi Flavonoides

Authors

  • Rye Yong Song Researcher, Department of Dental Caries and Oral Medicine Research, Faculty of Dentistry, Pyongyang University of Medical sciences, Central District, Pyongyang, Democratic People’s Republic of Korea
  • Ki Ho Rim Professor and PhD Chief, Department of Dental Caries and Oral Medicine Research, Faculty of Dentistry, Pyongyang University of Medical sciences, Central District, Pyongyang, Democratic People’s Republic of Korea
  • Sun Yong Choe Researcher, Department of Dental Caries and Oral Medicine Research, Faculty of Dentistry, Pyongyang University of Medical sciences, Central District, Pyongyang, Democratic People’s Republic of Korea
  • Ju Song Choe Professor and PhD Lecturer, Department of Dermatology, Faculty of Clinical Medicine, Pyongyang University of Medical Sciences, Central District, Pyongyang, Democratic People’s Republic of Korea
  • Yong Sil Ri Researcher, Department of Oral Medicine, Rason Hospital of Dentistry, Rason, Democratic People’s Republic of Korea
  • Sang Jun Kim Researcher, Dental Department at Affiliated Hospital of Pyonyang University of Medical Sciences
  • Chol Jun Hwang Researcher, Department of Dental Caries and Oral Medicine Research, Faculty of Dentistry, Pyongyang University of Medical sciences, Central District, Pyongyang, Democratic People’s Republic of Korea

DOI:

https://doi.org/10.37591/rrjod.v13i2.2946

Keywords:

Recurrent aphthous ulcer, baicalin, Scutellaria baicalensis Georgi flavonoids

Abstract

We report a case of 52-year-old woman with severe recurrent aphthous ulcer, successfully treated by Scutellaria baicalensis Georgi flavonoides (SBFs). SBFs triturate was administered orally to the patient thrice daily for 13 consecutive days. After administration of this medicine, aphthous ulcers haven’t recurred for 3 years and 1 months by now.

References

Challacombe SJ, Alsahaf S, Tappuni A. Recurrent aphthous stomatitis: towards evidence-based treatment?. Current Oral Health Reports. 2015 ;2(3):158-67.

Mimura MA, Hirota SK, Sugaya NN,et al. Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial. Clinics. 2009;64:193-8.

Scully C, Porter S. Oral mucosal disease: recurrent aphthous stomatitis. British Journal of Oral and Maxillofacial Surgery. 2008;46(3):198-206.

Pakfetrat A, Mansourian A, Momen-Heravi F,et al. Comparison of colchicine versus prednisolone in recurrent aphthous stomatitis: A double-blind randomized clinical trial. Clinical and investigative medicine. 2010:E189-95..

Hello M, Barbarot S, Bastuji-Garin Set al. Use of thalidomide for severe recurrent aphthous stomatitis: a multicenter cohort analysis. Medicine. 2010;89(3):176-82.

Cao Y, Mao X, Sun Cet al. Baicalin attenuates global cerebral ischemia/reperfusion injury in gerbils via anti-oxidative and anti-apoptotic pathways. Brain research bulletin. 2011 ;85(6):396-402.

Qin Y. Construction of rat models of recurrent aphthous ulcer and the intervention of baicalin. Chinese Journal of Tissue Engineering Research. 2015;19(40):6504.

Belenguer-Guallar I, Jiménez-Soriano Y, Claramunt-Lozano A. Treatment of recurrent aphthous stomatitis. A literature review. Journal of clinical and experimental dentistry. 2014;6(2):e168.

Tappuni AR, Kovacevic T, Shirlaw PJ,et al. Clinical assessment of disease severity in recurrent aphthous stomatitis. Journal of Oral Pathology & Medicine. 2013 ;42(8):635-41.

Tang W, Eisenbrand G. Scutellaria baicalensis Georgi. InChinese drugs of plant origin 1992 (pp. 919-929).

Yang B, Bai H, Sa Y,et al. Inhibiting EMT, stemness and cell cycle involved in baicalin-induced growth inhibition and apoptosis in colorectal cancer cells. Journal of Cancer. 2020;11(8):2303.

Downloads

Published

2022-09-02

Issue

Vol. 13 No. 2 (2022)

Section

Case Study

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.